Form S-1
CHIASMA, INC filed this Form S-1 on 06/15/2015
Document Outline
Entire Document (5640.8 KB)
Subdocument 1 - S-1 - S-1
Page 1 - As filed with the Securities and Exchange Commission on June 15, 2015
Page 2 - The information in this preliminary prospectus is not complete and may be changed. We may not sell t
Page 3 - TABLE OF CONTENTS
Page 4 - PROSPECTUS SUMMARY
Page 5 - N/A
Page 6 - Commercialization Strategy
Page 7 - Strategy
Page 8 - Corporate Information
Page 9 - Implications of Being an Emerging Growth Company
Page 10 - THE OFFERING
Page 11 - N/A
Page 12 - SUMMARY CONSOLIDATED FINANCIAL DATA
Page 13 - N/A
Page 14 - RISK FACTORS
Page 15 - If we are not able to obtain required regulatory approvals for oral octreotide, we will not be able
Page 16 - N/A
Page 17 - The FDA may determine that our NDA for oral octreotide for the maintenance therapy of acromegaly is
Page 18 - Our development, regulatory and commercialization strategy for oral octreotide depends, in part, on
Page 19 - Clinical drug development involves a lengthy and expensive process with an uncertain outcome, result
Page 20 - N/A
Page 21 - Changes in regulatory requirements and guidance may also occur and we may need to amend clinical tri
Page 22 - Even if we receive regulatory approval of oral octreotide, we may still face future development and
Page 23 - We face substantial competition from larger companies with considerable resources that already have
Page 24 - The number of patients suffering from acromegaly is small, and has not been established with precisi
Page 25 - Even if we receive regulatory approval of oral octreotide, it may not achieve an adequate level of a
Page 26 - We currently have no sales and marketing organization and, as a company, have not commercialized any
Page 27 - We will need to grow the size of our organization in order to establish our sales and marketing infr
Page 28 - Even if we obtain marketing approval of oral octreotide or any future product candidates we may deve
Page 29 - If we do not achieve our projected development and commercialization goals in the timeframes we anno
Page 30 - Oral octreotide and other products we may develop may not be commercially viable if we fail to obtai
Page 31 - The longer term growth of our business depends on our efforts to leverage our TPE platform to expand
Page 32 - Our ability to develop a viable pipeline of potential future products may require us to enter into l
Page 33 - Our relationships with customers and third-party payors will be subject to applicable anti-kickback,
Page 34 - Legislative or regulatory reform of the health care system in the United States and foreign jurisdic
Page 35 - King v. Burwell
Page 36 - We may not be able to maintain our current product liability coverage, and, even if we do, our cover
Page 37 - N/A
Page 38 - If our third-party manufacturers use hazardous and biological materials in a manner that causes inju
Page 39 - We rely, and will rely in the future, on third parties to conduct our nonclinical studies and clinic
Page 40 - We have not generated any revenue from any commercial products and may never be profitable.
Page 41 - We may need additional capital to support our growth, which may be difficult to obtain and restrict
Page 42 - Risks Related to Our Business and Industry
Page 43 - Our employees, independent contractors, consultants, commercial partners, principal investigators, C
Page 44 - Laws and regulations governing conduct of international operations may negatively impact our develop
Page 45 - Risks Related to Our Intellectual Property
Page 46 - inter partes
Page 47 - inter partes
Page 48 - Obtaining and maintaining our patent protection depends on compliance with various procedural, docum
Page 49 - Oral octreotide or any future products we may develop may infringe the intellectual property rights
Page 50 - Changes in either U.S. or foreign patent law or interpretation of such laws could diminish the value
Page 51 - If our trademarks are not adequately protected, then we may not be able to build name recognition in
Page 52 - Our research and development and administrative facilities and one of our third-party manufacturers
Page 53 - Our directors, executive officers and principal stockholders exercise significant control over our c
Page 54 - Our amended and restated certificate of incorporation and amended and restated bylaws provide that t
Page 55 - The trading price of our common stock may be volatile, and your investment in our common stock could
Page 56 - We may be subject to securities litigation, which is expensive and could divert our management s att
Page 57 - We have never paid dividends on our capital stock and we do not anticipate paying any dividends in t
Page 58 - If we fail to maintain proper and effective internal controls, our ability to produce accurate finan
Page 59 - If securities or industry analysts do not publish research or publish inaccurate or unfavorable rese
Page 60 - CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 61 - INDUSTRY AND MARKET DATA
Page 62 - USE OF PROCEEDS
Page 63 - DIVIDEND POLICY
Page 64 - CAPITALIZATION
Page 65 - N/A
Page 66 - DILUTION
Page 67 - N/A
Page 68 - SELECTED CONSOLIDATED FINANCIAL DATA
Page 69 - N/A
Page 70 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 71 - Roche License Agreement
Page 72 - Financial Overview
Page 73 - Marketing, General and Administrative
Page 74 - Critical Accounting Policies and Use of Estimates
Page 75 - Stock-based Compensation
Page 76 - Results of Operations for the Three Months Ended March 31, 2014 and 2015
Page 77 - Marketing, General and Administrative
Page 78 - Research and Development
Page 79 - Other Expense, net
Page 80 - Plan of Operations and Future Funding Requirements
Page 81 - Cash Flows
Page 82 - Contractual Obligations and Contingent Liabilities
Page 83 - Common Stock Valuation
Page 84 - Common Stock Valuation Methodologies
Page 85 - Retrospective Valuations
Page 86 - March 16, 2015 Valuation
Page 87 - June 14, 2015 Valuation
Page 88 - N/A
Page 89 - Stock Option Grants
Page 90 - JOBS Act
Page 91 - BUSINESS
Page 92 - N/A
Page 93 - Strategy
Page 94 - N/A
Page 95 - Our Product Candidate Pipeline
Page 96 - Incidence and Prevalence of Acromegaly and Current Treatment Landscape
Page 97 - Our Solution: Oral Octreotide
Page 98 - Clinical Program for Oral Octreotide in Acromegaly
Page 99 - Phase 3 Clinical Trial Design
Page 100 - Overall Phase 3 Response in mITT Group vs. Baseline
Page 101 - Reduced Number of Acromegaly Symptoms at Conclusion of Oral Octreotide Trial
Page 102 - Planned Phase 3 Clinical Trial
Page 103 - Design of Planned Phase 3 to Support EMA Approval
Page 104 - Suppression of GH Levels in Healthy Volunteers
Page 105 - Our Proprietary Transient Permeability Enhancer Technology Platform
Page 106 - Our TPE Platform
Page 107 - Commercialization Strategy
Page 108 - Competition
Page 109 - Patents
Page 110 - Patent Term
Page 111 - N/A
Page 112 - in vitro
Page 113 - N/A
Page 114 - 505(b)(2) Approval Process
Page 115 - Other Regulatory Matters
Page 116 - U.S. Marketing Exclusivity
Page 117 - Coverage and Reimbursement
Page 118 - Anti-Kickback and False Claims Laws and Other Regulatory Matters
Page 119 - N/A
Page 120 - Affordable Health Care Act and Other Reform Initiatives
Page 121 - King v. Burwell
Page 122 - European Union Drug Review and Approval
Page 123 - Employees
Page 124 - MANAGEMENT
Page 125 - Roni Mamluk, Ph.D.
Page 126 - Non-Employee Directors
Page 127 - Vincent Miles, Ph.D.
Page 128 - Board Composition and Election of Directors
Page 129 - Staggered Board
Page 130 - Compensation Committee
Page 131 - Nominating and Corporate Governance Committee
Page 132 - Code of Business Conduct and Ethics
Page 133 - EXECUTIVE COMPENSATION
Page 134 - 2014 Outstanding Equity Awards at Fiscal Year-End
Page 135 - Roni Mamluk, Ph.D.
Page 136 - Chaime Orlev.
Page 137 - 2014 Director Compensation
Page 138 - Compensation Risk Assessment
Page 139 - 2008 Stock Incentive Plan
Page 140 - 2015 Stock Option and Incentive Plan
Page 141 - N/A
Page 142 - Employee Stock Purchase Plan
Page 143 - Senior Executive Cash Incentive Bonus Plan
Page 144 - 401(k) Plan
Page 145 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Page 146 - Series D Financing
Page 147 - Exchange of Previously Outstanding Preferred Stock
Page 148 - Indemnification Agreements
Page 149 - Services and Consulting Agreement
Page 150 - PRINCIPAL STOCKHOLDERS
Page 151 - N/A
Page 152 - N/A
Page 153 - DESCRIPTION OF CAPITAL STOCK
Page 154 - Registration Rights
Page 155 - Expiration of Registration Rights
Page 156 - Authorized but Unissued Shares
Page 157 - Transfer Agent and Registrar
Page 158 - SHARES ELIGIBLE FOR FUTURE SALE
Page 159 - Lock-up Agreements
Page 160 - MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS
Page 161 - This discussion is for general information only and is not tax advice. Accordingly, all prospective
Page 162 - Gain on Sale, Exchange or Other Disposition of Our Common Stock
Page 163 - Withholding and Information Reporting Requirements FATCA
Page 164 - UNDERWRITING
Page 165 - Lock-Up Agreements
Page 166 - Offering Price Determination
Page 167 - Stabilization, Short Positions and Penalty Bids
Page 168 - Listing on The NASDAQ Global Market
Page 169 - European Economic Area
Page 170 - Notice to Residents of Canada
Page 171 - LEGAL MATTERS
Page 172 - INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page 173 - CHIASMA, INC.
Page 174 - CHIASMA, INC.
Page 175 - CHIASMA, INC.
Page 176 - CHIASMA, INC.
Page 177 - CHIASMA, INC.
Page 178 - Use of Estimates
Page 179 - N/A
Page 180 - 3. Accrued Expenses and Other Current Liabilities
Page 181 - 6. Warrants
Page 182 - 9. Subsequent events
Page 183 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 184 - CHIASMA, INC.
Page 185 - CHIASMA, INC.
Page 186 - CHIASMA, INC.
Page 187 - CHIASMA, INC.
Page 188 - CHIASMA, INC.
Page 189 - CHIASMA, INC.
Page 190 - Use of estimates
Page 191 - Concentrations of credit risk
Page 192 - Employment termination costs
Page 193 - Long-term purchase obligation
Page 194 - Warrants
Page 195 - Contingent liabilities
Page 196 - 3. Net Loss Per Share Attributable to Common Stockholders
Page 197 - 5. Accrued Expenses and Other Current Liabilities
Page 198 - 6. License Agreement
Page 199 - 8. Warrants
Page 200 - 9. Redeemable Convertible Preferred Stock
Page 201 - Optional conversion
Page 202 - 10. Common Stock
Page 203 - Stock options
Page 204 - 12. Income Taxes
Page 205 - N/A
Page 206 - N/A
Page 207 - 13. Commitments and Contingencies
Page 208 - 15. Employee Benefit Plan
Page 209 - Shares
Page 210 - Part II
Page 211 - Item 15. Recent Sales of Unregistered Securities
Page 212 - Item 16. Exhibits and financial statement schedules
Page 213 - N/A
Page 214 - SIGNATURES
Page 215 - EXHIBIT INDEX
Subdocument 2 - EX-3.2 - EX-3.2
Page 1 - Exhibit 3.2
Page 2 - Common Stock
Page 3 - UNDESIGNATED PREFERRED STOCK
Page 4 - Vacancies
Page 5 - LIMITATION OF LIABILITY
Page 6 - AMENDMENT OF CERTIFICATE OF INCORPORATION
Page 7 - N/A
Subdocument 3 - EX-3.3 - EX-3.3
Page 1 - Exhibit 3.3
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - ARTICLE I
Page 5 - Quorum
Page 6 - Conduct of Meetings
Page 7 - Notice of Taking of Corporate Action
Page 8 - Action at Meeting
Page 9 - Action by Consent
Page 10 - Qualification
Page 11 - Treasurer and Assistant Treasurers
Page 12 - Transfers
Page 13 - Regulations
Page 14 - Certificate of Incorporation
Subdocument 4 - EX-3.4 - EX-3.4
Page 1 - Exhibit 3.4
Page 2 - provided
Page 3 - N/A
Page 4 - N/A
Page 5 - General
Page 6 - Special Meetings
Page 7 - Quorum
Page 8 - Voting and Proxies
Page 9 - Inspectors of Elections
Page 10 - Regular Meetings
Page 11 - Action by Consent
Page 12 - ARTICLE III
Page 13 - Chairman of the Board
Page 14 - ARTICLE IV
Page 15 - Replacement of Certificates
Page 16 - Indemnification of Directors and Officers
Page 17 - Actions, Suits and Proceedings By or In the Right of the Corporation
Page 18 - Determination
Page 19 - Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition
Page 20 - Non-Exclusivity of Rights
Page 21 - ARTICLE VI
Page 22 - Section 8
Subdocument 5 - EX-4.2 - EX-4.2
Page 1 - Exhibit 4.2
Page 2 - Exhibit B
Page 3 - Offered Securities
Page 4 - N/A
Page 5 - Required Registrations
Page 6 - Incidental Registration
Page 7 - Registration Procedures
Page 8 - N/A
Page 9 - Allocation of Expenses
Page 10 - N/A
Page 11 - Other Matters with Respect to Underwritten Offerings
Page 12 - Information by Stockholder
Page 13 - Rule 144 Requirements
Page 14 - N/A
Page 15 - Assigning Investor
Page 16 - Debt
Page 17 - Additional Rights of the Purchasers
Page 18 - Excess Amount
Page 19 - Compliance with Laws
Page 20 - Material Changes and Litigation
Page 21 - Board of Directors
Page 22 - International Investment and Trade in Services Survey Act
Page 23 - Calculation of Share Numbers
Page 24 - Exhibit A
Page 25 - Special Series D Vote
Page 26 - Exhibit C
Page 27 - [Signature Page to Amended and Restated Investor Rights Agreement]
Page 28 - [Signature Page to Amended and Restated Investor Rights Agreement]
Page 29 - [Signature Page to Amended and Restated Investor Rights Agreement]
Page 30 - [Signature Page to Amended and Restated Investor Rights Agreement]
Page 31 - EXHIBIT A
Page 32 - EXHIBIT B
Page 33 - N/A
Page 34 - EXHIBIT C
Page 35 - OMNIBUS AMENDMENT AGREEMENT
Page 36 - Series E Purchase Price
Page 37 - Exhibit J
Page 38 - Brokers
Page 39 - Investor Majority
Page 40 - Amendments and Waivers
Page 41 - Special Series D Vote
Page 42 - Company Certificate
Page 43 - Voting of Shares
Page 44 - Series D Preferred Stock
Page 45 - N/A
Page 46 - N/A
Page 47 - N/A
Page 48 - N/A
Page 49 - N/A
Page 50 - N/A
Page 51 - N/A
Subdocument 6 - EX-4.3 - EX-4.3
Page 1 - Exhibit 4.3
Page 2 - Attachment A
Page 3 - Delivery; Certificate
Page 4 - Stock Dividends
Page 5 - provided, however
Page 6 - Rights of Stockholders
Page 7 - Counterparts
Page 8 - WARRANT SIGNATURE PAGE
Page 9 - ATTACHMENT A
Page 10 - ATTACHMENT B
Subdocument 7 - EX-4.4 - EX-4.4
Page 1 - EXHIBIT 4.4
Page 2 - Conversion Right
Page 3 - Sale Exercise
Page 4 - Stock Dividends
Page 5 - provided, however,
Page 6 - Rights of Stockholders
Page 7 - Counterparts
Page 8 - ACKNOWLEDGED:
Page 9 - ATTACHMENT A
Page 10 - ATTACHMENT B
Page 11 - N/A
Subdocument 8 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - Date of Grant
Page 6 - Date of Start
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - CHIASMA, INC.
Page 14 - FORM OF OPTION AGREEMENT
Page 15 - Grantee s Options
Page 16 - Restricted Shares
Page 17 - Rule 144
Page 18 - Transfer Notice
Page 19 - Transferees of Transfer Shares
Page 20 - N/A
Page 21 - [Remainder of page intentionally left blank]
Page 22 - IN WITNESS WHEREOF
Subdocument 9 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - Delegation to Officers
Page 3 - Incentive Stock Options
Page 4 - Restricted Stock: Restricted Stock Units
Page 5 - Adjustments for Changes in Common Stock and Certain Other Events
Page 6 - Consequences of a Reorganization Event on Restricted Stock Awards
Page 7 - General Provisions Applicable to Awards
Page 8 - Amendment of Award
Page 9 - Amendment of Plan
Page 10 - CHIASMA, INC.
Page 11 - Granted Under 2008 Stock Incentive Plan
Page 12 - Termination of Relationship with the Company
Page 13 - Company Right to Purchase
Page 14 - provided
Page 15 - Withholding
Page 16 - N/A
Page 17 - N/A
Page 18 - Granted Under 2008 Stock Incentive Plan
Page 19 - Termination of Relationship with the Company
Page 20 - Notice of Proposed Transfer
Page 21 - Exempt Transactions
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - 1. Definitions
Page 26 - 2. General
Page 27 - 4. 102 Trustee Awards
Page 28 - 4.4 Rights as Stockholder:
Page 29 - 4.7 Conditions of Issuance:
Page 30 - 8. Currency Exchange Rates
Page 31 - N/A
Page 32 - OPTION AGREEMENT
Page 33 - N/A
Page 34 - N/A
Page 35 - N/A
Page 36 - provided, however, that in the case of a transfer pursuant to clause 5.1.5(a) above, such Shares sha
Page 37 - N/A
Page 38 - N/A
Page 39 - [Signature Page Follows]
Page 40 - In Witness Whereof, the parties hereto have caused this Option Agreement to be duly executed on the
Page 41 - CHIASMA, INC.
Page 42 - Representations, Warranties and Covenants.
Page 43 - Repurchase Option; Right of First Refusal
Page 44 - Exercise Application
Subdocument 10 - EX-10.5 - EX-10.5
Page 1 - Exhibit 10.5
Page 2 - Calculation of Corporate Performance Goals
Page 3 - Amendment and Termination
Subdocument 11 - EX-10.6 - EX-10.6
Page 1 - Exhibit 10.6
Page 2 - Stock Options:
Page 3 - N/A
Page 4 - N/A
Page 5 - Termination of Employment as a Result of Death, Disability, Your Resignation or a Termination by the
Page 6 - N/A
Page 7 - Interpretation, Amendment and Enforcement
Page 8 - N/A
Subdocument 12 - EX-10.7 - EX-10.7
Page 1 - Exhibit 10.7
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - Company
Page 6 - In witness whereof, I have signed this Acceptance and Release Form this day
Page 7 - Details of Rights and Final Settlement Account
Subdocument 13 - EX-10.8 - EX-10.8
Page 1 - Exhibit 10.8
Page 2 - Signing Bonus.
Page 3 - Termination Benefits
Page 4 - N/A
Page 5 - Termination of Employment as a Result of Death, Disability, Your Resignation or a Termination by the
Page 6 - N/A
Page 7 - Interpretation, Amendment and Enforcement
Page 8 - Assignment
Page 9 - N/A
Page 10 - RELEASE OF CLAIMS
Page 11 - Ongoing Obligations of the Executive
Page 12 - Binding Nature of Release
Page 13 - Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement
Page 14 - Exhibit A
Page 15 - 8. Non-Competition and Non-Solicitation
Page 16 - 13. Publications and Public Statements
Page 17 - I UNDERSTAND THAT THIS AGREEMENT AFFECTS IMPORTANT RIGHTS. BY SIGNING BELOW, I CERTIFY THAT I HAVE R
Page 18 - EXHIBIT A
Subdocument 14 - EX-10.9 - EX-10.9
Page 1 - Exhibit 10.9
Page 2 - N/A
Page 3 - N/A
Page 4 - IN WITNESS WHEREOF
Page 5 - ANNEX A to
Page 6 - ex gratia
Page 7 - N/A
Page 8 - ANNEX A-1
Page 9 - N/A
Page 10 - Annex B to
Page 11 - General
Page 12 - N/A
Subdocument 15 - EX-10.11 - EX-10.11
Page 1 - Exhibit 10.11
Page 2 - Now therefore, it is hereby stipulated, conditioned and warranted
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - Representations and Undertakings of the Lessor
Page 7 - N/A
Page 8 - N/A
Page 9 - Replacement Lessee
Page 10 - Rental Fees
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - pro rata
Page 15 - inter alia
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - Changes and Additions
Page 23 - N/A
Page 24 - Appendix D
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - control
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - Now therefore, the parties hereby affix their signatures on September 5, 2008 in the place and on th
Page 40 - Appendix A
Page 41 - APPENDIX B
Page 42 - N/A
Page 43 - APPENDIX C
Page 44 - N/A
Page 45 - N/A
Page 46 - N/A
Page 47 - N/A
Page 48 - N/A
Page 49 - APPENDIX D
Page 50 - THE MANAGEMENT COMPANY S POWERS
Page 51 - PERFORMANCE OF WORKS BY THE MANAGEMENT COMPANY
Page 52 - MANAGEMENT AND MAINTENANCE FEES
Page 53 - THE TERM OF THE PRINCIPLES OF MANAGEMENT
Page 54 - APPENDIX F
Page 55 - APPENDIX G
Page 56 - APPENDIX H-1
Page 57 - HEAD C
Page 58 - APPENDIX H-2
Page 59 - N/A
Page 60 - APPENDIX J SPECIAL TERMS
Page 61 - Section 6 Purpose of the Lease
Page 62 - Section 9 Rental Fees
Page 63 - N/A
Page 64 - Section 11 Other Payments
Page 65 - N/A
Page 66 - N/A
Page 67 - N/A
Page 68 - Section 18 Parking Lot
Page 69 - Section 21 Insurance
Page 70 - APPENDIX L
Page 71 - ATAR
Page 72 - ATAR
Page 73 - ATAR
Page 74 - ATAR
Page 75 - ATAR
Page 76 - ATAR
Page 77 - ATAR
Page 78 - ATAR
Page 79 - N/A
Page 80 - Amendment to Lease Agreement Dated as of September 5, 2008
Page 81 - Section 2 Definitions
Page 82 - Section 11 Other Payments
Page 83 - Section 25 Painting the Leased Property
Page 84 - Amendment to Lease Agreement
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - Amendment to Lease Agreement Dated as of September 5, 2008
Page 89 - N/A
Page 90 - N/A
Page 91 - Amendment to Lease Agreement
Page 92 - N/A
Page 93 - N/A
Page 94 - N/A
Page 95 - Amendment to Lease Agreement
Page 96 - Now therefore, it is hereby stipulated, conditioned and warranted between the parties as follows:
Page 97 - N/A
Page 98 - N/A
Page 99 - Appendix A
Page 100 - N/A
Page 101 - N/A
Page 102 - Appendix C
Page 103 - Amendment to Lease Agreement dated as of September 5, 2008
Page 104 - N/A
Page 105 - N/A
Page 106 - Amendment to Lease Agreement Dated as of September 5, 2008
Page 107 - N/A
Page 108 - Amendment to Lease Agreement Dated as of September 5, 2008
Page 109 - N/A
Page 110 - Amendment to Lease Agreement Dated as of September 5, 2008
Page 111 - Now therefore, it is hereby stipulated, conditioned and warranted between the parties as follows:
Subdocument 16 - EX-10.12 - EX-10.12
Page 1 - Exhibit 10.12
Page 2 - FF E
Page 3 - Original Security Deposit
Page 4 - Section 12
Page 5 - Section 18
Page 6 - Sublessor Liability and Default
Page 7 - Services Under Lease
Page 8 - Brokers
Page 9 - IN WITNESS WHEREOF
Page 10 - EXHIBIT A
Page 11 - LEASE
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - LEASE TEXT
Page 16 - Security Deposit
Page 17 - C
Page 18 - Operating Statement
Page 19 - provided
Page 20 - Insurance
Page 21 - Section 15
Page 22 - provided
Page 23 - Building Occupant
Page 24 - subsection 12.B
Page 25 - Indemnification and Liability
Page 26 - Fire Casualty-Eminent Domain
Page 27 - provided, however
Page 28 - provided
Page 29 - Surrender
Page 30 - Extension Notice Date
Page 31 - Quiet Enjoyment
Page 32 - Additional Right of Landlord Cure
Page 33 - N/A
Page 34 - N/A
Page 35 - N/A
Page 36 - LEASE RIDER
Page 37 - provided
Page 38 - EXHIBIT A
Page 39 - EXHIBIT A-1
Page 40 - Not to scale. Layout is approximate.
Page 41 - EXHIBIT A-2
Page 42 - EXHIBIT B
Page 43 - N/A
Page 44 - provided
Page 45 - EXHIBIT C
Page 46 - EXHIBIT D
Page 47 - FIRST AMENDMENT OF LEASE
Page 48 - N/A
Page 49 - N/A
Page 50 - N/A
Page 51 - N/A
Page 52 - N/A
Page 53 - N/A
Page 54 - N/A
Page 55 - EXHIBIT A
Page 56 - EXHIBIT B-1
Page 57 - EXHIBIT B
Page 58 - EXHIBIT C
Subdocument 17 - EX-21.1 - EX-21.1
Page 1 - Exhibit 21.1
Subdocument 18 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1